HCWB HCW Biologics
- 1.200
- +0.040+3.45%
HCW Biologics News
HCW Biologics Says Due To Default Issue, Concluded Financial Statements As Of & For Year Ended Dec 31, 2023 Should Be Restated & No Longer Be Relied Upon
HCW Biologics Says Due To Default Issue, Concluded Financial Statements As Of & For Year Ended Dec 31, 2023 Should Be Restated & No Longer Be Relied Upon
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersPaxMedica (NASDAQ:PXMD) stock moved upwards by 104.2% to $0.84 during Friday's pre-market session. The market value of their outstanding shares is at $6.2 million. Allarity Therapeutics (NASDAQ
HCW Biologics: A Strong Buy on Promising Clinical Results and Strategic Advancements
HCW Biologics Q4 2023 GAAP EPS $(0.15) Misses $(0.14) Estimate, Sales $1.341M Beat $900.000K Estimate
HCW Biologics (NASDAQ:HCWB) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.14) by 7.14 percent. The company reported quarterly sales of $1.341 milli
HCW Biologics: Continue With Other Fundraising Efforts That We Are Targeting to Complete in the Next Three to Six Mos >HCWB
HCW Biologics: Continue With Other Fundraising Efforts That We Are Targeting to Complete in the Next Three to Six Mos >HCWB
HCW Biologics: As of Dec 31, 2023, There Was Substantial Doubt About Our Ability to Continue as a Going Concern >HCWB
HCW Biologics: As of Dec 31, 2023, There Was Substantial Doubt About Our Ability to Continue as a Going Concern >HCWB
HCW Biologics: Since That Time Successful Financings of $12.5M, Have Received Funds or Have Legally Binding Commitment to So >HCWB
HCW Biologics: Since That Time Successful Financings of $12.5M, Have Received Funds or Have Legally Binding Commitment to So >HCWB
HCW Biologics 4Q Loss/Shr 30c >HCWB
HCW Biologics 4Q Loss/Shr 30c >HCWB
Press Release: HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights
HCW Biologics Inc. today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.
Chief Financial Officer of HCW Biologics Rebecca Byam Buys 122% More Shares
Those following along with HCW Biologics Inc. (NASDAQ:HCWB) will no doubt be intrigued by the recent purchase of shares by Rebecca Byam, Chief Financial Officer of the company, who spent a stonking US
HCW Biologics Executives Boost Investment With Share Purchase
HCW Biologics Said Terminated Its Credit Agreement With Prime Capital Ventures Dated April 21, 2023, As Allowed Under The Agreement Terms, Due To Repeated Funding Delays And Related Concerns
HCW Biologics Said Terminated Its Credit Agreement With Prime Capital Ventures Dated April 21, 2023, As Allowed Under The Agreement Terms, Due To Repeated Funding Delays And Related Concerns
HCW Biologics Receives Buy Rating: Strong Financial Position and Promising Clinical Data Validate Investment Opportunity
Analysts Are Bullish on Top Healthcare Stocks: HCW Biologics (HCWB), Urogen Pharma (URGN)
HCW Biologics GAAP EPS of -$0.14, Revenue of $174.77M
Earnings Flash (HCWB) HCW BIOLOGICS Reports Q3 Revenue $853,102
07:12 AM EST, 11/14/2023 (MT Newswires) -- Earnings Flash (HCWB) HCW BIOLOGICS Reports Q3 Revenue $853,102
HCW Biologics 3Q Loss/Shr 14c >HCWB
HCW Biologics 3Q Loss/Shr 14c >HCWB
Promising Phase 1 Results and Potential Synergies With PD-1 Inhibitors Bolster Buy Rating for HCW Biologics
Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
Showed HCW9218 clinical safety and tumor response endpointsfor 15 patients with heavily pretreated advanced solid tumors Results in ovarian cancer patients outpace other indications, with 66% stable disease MIRAMAR,
Promising Clinical Data and Future Plans Boost HCW Biologics: An Analysis of Soumit Roy's Buy Recommendation
Analysis
Price Target
No Data
